
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is expected to see growth in their key products, Verzenio and Jardiance, for cancer and cardiometabolic diseases. Their strong financials, with estimated product sales of $120M and an increase in their global POS, make them well-positioned to outperform their competitors. Additionally, with a focus on diversity and inclusivity in clinical trials and a strong development pipeline, their long-term outlook remains promising.
Bears say
Eli Lilly is facing several challenges that could have a negative impact on its stock performance. In particular, the company's recent earnings report showed a lower than expected revenue and earnings per share, and there are concerns about the company's pricing dynamics, competition, and pricing pressures from payors and regulators. Additionally, there are potential risks related to the company's pipeline, including negative trial results and competition from novel therapies. Furthermore, LLY's high valuation could face pressure in the face of concerning newsflow and challenges such as decreasing pharmacy reimbursement and uncertain utilization.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares